Zalmanovici Trestioreanu Anca, Lador Adi, Sauerbrun-Cutler May-Tal, Leibovici Leonard
Department of Family Medicine, Beilinson Hospital, Rabin Medical Center, 39 Jabotinski Street, Petah Tikva, Israel, 49100.
Cochrane Database Syst Rev. 2015 Apr 8;4(4):CD009534. doi: 10.1002/14651858.CD009534.pub2.
Asymptomatic bacteriuria is commonly detected in women aged up to 60 years, patients with diabetes, and the elderly. The benefit of antibiotic treatment for this condition is controversial.
To assess the effectiveness and safety of antibiotics treatment for asymptomatic bacteriuria in adults. Specific objectives were to assess 1) the effectiveness of antibiotics for preventing development of symptomatic UTI, UTI-related complications, overall mortality, UTI-related mortality, and resolution of bacteriuria; 2) the development of resistance to antibiotic treatment by comparing resistance of grown bacteria in urine before and after therapy; and 3) the frequency of adverse events.
We searched the Cochrane Renal Group's Specialised Register up to 24 February 2015 through contact with the Trials' Search Co-ordinator using search terms relevant to this review.
Randomised controlled trials (RCTs) and quasi-RCTs comparing antibiotics to placebo or no treatment for asymptomatic bacteriuria in adults were included. The outcomes of interest were the development of symptomatic urinary tract infection (UTI), complications, death, any adverse event, development of antibiotic resistance, bacteriological cure, and decline in kidney function.
Two authors independently extracted the data and assessed study quality. Statistical analyses were performed using the random effects model and the results expressed as risk ratios (RR) with 95% confidence intervals (CI).
We included nine studies (1614 participants) in this review. Symptomatic UTI (RR 1.11, 95% CI 0.51 to 2.43), complications (RR 0.78, 95% CI 0. 35 to 1.74), and death (RR 0.99, 95% CI 0.70 to 1.41) were similar between the antibiotic and placebo or no treatment arms. Antibiotics were more effective for bacteriological cure (RR 2.32, 95% CI 1.11 to 4.83) but also more adverse events developed in this group (RR 3.77, 95% CI 1.40 to 10.15). No decline in the kidney function was observed across the studies; minimal data were available on the emergence of resistant strains after antimicrobial treatment.The included studies were of medium and high quality, used different treatments for different durations of treatment and follow-up, different populations, but this did not appear to influence the results of review.
AUTHORS' CONCLUSIONS: No differences were observed between antibiotics versus no treatment of asymptomatic bacteriuria for the development of symptomatic UTI, complications or death. Antibiotics were superior to no treatment for the bacteriological cure but with significantly more adverse events. There was no clinical benefit from treating asymptomatic bacteriuria in the studies included in this review.
无症状菌尿常见于60岁以下女性、糖尿病患者及老年人中。针对这种情况使用抗生素治疗的益处存在争议。
评估抗生素治疗成人无症状菌尿的有效性和安全性。具体目标是评估:1)抗生素预防有症状的尿路感染(UTI)、UTI相关并发症、全因死亡率、UTI相关死亡率以及菌尿症消退的有效性;2)通过比较治疗前后尿液中生长细菌的耐药性,评估抗生素治疗后耐药性的产生情况;3)不良事件的发生频率。
我们通过与试验检索协调员联系,使用与本综述相关的检索词,检索了截至2015年2月24日的Cochrane肾脏组专业注册库。
纳入比较抗生素与安慰剂或不治疗成人无症状菌尿的随机对照试验(RCT)和半随机对照试验。感兴趣的结局包括有症状的尿路感染(UTI)的发生、并发症、死亡、任何不良事件、抗生素耐药性的产生、细菌学治愈以及肾功能下降。
两位作者独立提取数据并评估研究质量。采用随机效应模型进行统计分析,结果以风险比(RR)及95%置信区间(CI)表示。
本综述纳入了9项研究(1614名参与者)。抗生素组与安慰剂组或不治疗组在有症状的UTI(RR 1.11,95%CI 0.51至2.43)发生率、并发症(RR 0.78,95%CI 0.35至1.74)发生率和死亡率(RR 0.99,95%CI 0.70至1.41)方面相似。抗生素在细菌学治愈方面更有效(RR 2.32,95%CI 1.11至4.83),但该组发生的不良事件也更多(RR 3.77,95%CI 1.40至10.15)。各项研究均未观察到肾功能下降;关于抗菌治疗后耐药菌株出现的可用数据极少。纳入的研究质量为中等和高等,针对不同的治疗持续时间和随访时间、不同人群采用了不同的治疗方法,但这似乎并未影响综述结果。
在有症状的UTI、并发症或死亡的发生方面,抗生素治疗与不治疗无症状菌尿之间未观察到差异。抗生素在细菌学治愈方面优于不治疗,但不良事件明显更多。在本综述纳入的研究中,治疗无症状菌尿无临床益处。